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Infectious diseases have been a major
cause of death throughout history. The
changing causes of mortality in Australia
over the past century have been docu-
mented in a recent report from the Aus-
tralian Institute of Health and Welfare.1 In
Australia, the death rate in males from in-
fectious diseases fell from 283 deaths per
100,000 population in 1907 to about six in
1980, after which it almost doubled to 11
in 2000. In contrast, the death rate for cir-
culatory diseases increased from 437 per
100,000 of population in 1907 to 1,020 in
1968 before falling to 319 in 2000. For fe-
males, the death rate from infectious dis-
eases fell from 230 in 1907 to four per
100,000 population in 1980, before in-
creasing to seven in 2000. In the same pe-
riod, the average life expectancy at birth
increased by 23.6 years for males, from
53.8 years in 1900 to 77.4 in 2000 and by
25.1 years for females, from 57.5 to 82.6.
Classical medical teaching by Hippo-
crates and later Galen supported the con-
cept that infections were caused by
chemical miasmata (unhealthy emana-
tions) arising from swamps and unburied
corpses. Treatment was by removal of the
miasmata by ringing bells in the open and
letting birds fly around inside rooms. An
early example of a more rational approach
was the decision in 1647 by the town coun-
cillors of Aberdeen in Scotland to com-
mand the poisoning of rats and mice to
reduce the spread of plague; the last case
of bubonic plague in Scotland was in 1648.
The discovery of bacteria as the causative
agents of infection took several centuries.
In 1683, Anton van Leeuwenhoek of Delft
wrote to the Royal Society describing the
appearance of minute ‘animalcules’
under the microscope he had invented.
Louis Pasteur in 1861 demonstrated that
fermentation failed to take place when
organisms from the air were excluded
from heat-sterilised liquids. Robert Koch
received the Nobel Prize in 1905 following
his discoveries of the causative organisms
for anthrax (1876), tuberculosis (1882)
and cholera (1883). Koch is one of many
outstanding scientists who have been
awarded the Nobel Prize for their out-
standing contributions to understanding
pathogens.2
DEVELOPMENT OF ANTIBACTERIAL 
COMPOUNDS
The use of chemicals to selectively control
infections is a relatively recent advance in
Lindsay Brown BPharm (Hons) PhD
School of Biomedical Sciences, the 
University of Queensland, Australia
E-mail: l.brown@uq.edu.au
The introduction of new antibiotic compounds into therapy initiates the development
of resistance by the target bacteria. Resistance increases the risk of treatment failure with
potentially serious consequences. Local application of antibacterial compounds to the
eyes may lead to bacterial resistance in bacterial isolates from the eyes. The incidence
of resistant strains of common pathogens is probably increasing. As compounds can be
absorbed into the systemic circulation following ocular administration, the subsequent
low concentrations in the blood could provide the selective pressure for the survival of
resistant bacteria in the body. Despite this possibility, there are no reports of systemic
resistance in bacteria following ocular administration of antibacterial compounds. All
health-care professionals should be concerned about this possibility and continue to use
these important compounds with respect.
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medicine. Early attempts to produce
drugs with selective toxicity were unsuc-
cessful. At the start of the 20th Century,
Paul Ehrlich (Nobel Prize 1908) searched
for compounds to treat trypanosomiasis
(sleeping sickness in man), a protozoal
infection; the most effective compound
was an organic arsenical, salvarsan. In
1910, salvarsan was shown to cure syphilis
in man and this drug was the drug of
choice until 1945 when it was completely
replaced by the less toxic and more potent
penicillins. The first edition of Goodman
and Gilman’s textbook on The pharmacolog-
ical basis of therapeutics in 1941 devotes
more than 30 pages to the ‘important and
indispensable’ organic arsenicals, which
penicillins made redundant within a
decade. The first successful synthetic drug
against bacteria was the dye prontosil,
developed in 1933 by Gerhard Domagk
(Nobel Prize, 1939) as an effective treat-
ment against streptococcal infections in
mice and later in humans (including his
daughter as one of the first patients).
Prontosil was a pro-drug, metabolised to
the sulphonamide, sulphanilamide. The
development of the penicillins from Alex-
ander Fleming in 1928 to Howard Florey
and Ernst Chain at Oxford in the 1940s is
widely known.3 The development of the
antibiotics has been the subject of many
books, including analysis of the impact of
bacterial resistance.4
The key prerequisite for a chemical
compound to inhibit or kill parasites is
selectivity. Such selective toxicity depends
on the discovery of biochemical differ-
ences between the host and the pathogen
that can be exploited, so that the drug is
toxic to the pathogen but innocuous to
the host.5 There are three general classes
of biochemical reactions that are potential
targets: class I reactions that utilise glucose
to produce ATP and simple carbon com-
pounds, class II reactions utilising energy
and class I compounds to make small mol-
ecules such as amino acids and lastly, class
III reactions that convert small molecules
into macromolecules such as proteins,
nucleic acids and peptidoglycans.5 Class I
reactions are not promising targets, as
they are similar in humans and pathogens
and show redundance; class II and III
reactions are targets for all commonly
used antibacterial drugs.5
There are four mechanisms of action on
class II and III reactions that have been
exploited to provide selective toxicity for
pathogens. These mechanisms with drug
examples are:
1. interference with cell wall synthesis
(penicillins and cephalosporins)
2. inhibition of protein synthesis
(chloramphenicol, tetracyclines, mac-
rolides such as erythromycin, ami-
noglycosides such as gentamicin)
3. inhibition of key metabolic pathways
(sulphonamides, trimethoprim)
4. interference with nucleic acids (fluoro-
quinolones such as ciprofloxacin and
ofloxacin, antiviral compounds such as
vidarabine and acyclovir).5
The most widely used ocular antibiotics
are the fluoroquinolones, chlorampheni-
col and the aminoglycosides, such as
gentamicin. The fluoroquinolones inhibit
topoisomerase II, the enzyme that permits
replication by producing a negative super-
coil in DNA; chloramphenicol inhibits
transpeptidation during growth of the
peptide chain, while the aminoglycosides
block protein synthesis following misread-
ing of the RNA in the ribosome.5
DEVELOPMENT OF BACTERIAL 
RESISTANCE
The paradox of anti-infective treatment is
that the introduction of newer, effective
antibiotics into clinical medicine initiates
the development of resistance, leading to
a loss of effectiveness of the new drug.
Resistance is defined as a significant
increase in the drug concentrations in
the blood needed to inhibit bacterial
growth or cause bacterial death. The
development of resistance should be ex-
pected from the evolutionary principle
that organisms adapt genetically to
changes in their environment. The short
generation time and the presence of
large numbers of bacteria allow rapid
adaptation. Almost all Staphylococcus
strains were susceptible to the penicillins,
when they were introduced in the early
1940s. Resistance was first reported in
1944 and now virtually all strains are
resistant to the natural penicillins, ami-
nopenicillins and antipseudomonal peni-
cillins.3 Further developments have been
the emergence of methicillin-resistant
S. aureus (MRSA), vancomycin-resistant
enterococci (VRE) and fully vancomycin-
resistant strains (VRSA) with their associ-
ated health risks.6 Bacterial resistance
may result in treatment failure, possibly
increasing mortality rates and placing an
increased burden on health-care facilities.
The potential costs of health-care-
acquired infections are enormous, with
suggestions that MRSA alone increases
hospital costs annually by between US$1.5
and US$4.2 billion in the USA and £3 bil-
lion in the UK.7 Despite these costs, the
evidence suggests that control is highly
cost-effective.7
Bacteria have developed complex bio-
chemical mechanisms leading to resis-
tance.8–10 The four major biochemical
mechanisms of antibiotic resistance are
alteration of the target site, enzymatic
inactivation or modification of the com-
pound, decreased uptake or increased
efflux of the antibiotic compound and the
development of bypass pathways.9 Some
examples are alterations in the target pro-
tein for the aminoglycosides and mac-
rolides, upregulation of the enzymes that
inactivate the penicillins, the β-lactamases,
downregulation of membrane proteins
that  the  antibiotic  compound  requires
for cell entry, such as OmpF in E. coli for
entry of chloramphenicol, tetracyclines
and quinolones, or upregulation of pumps
that expel the antibiotic drug, such as the
fluoroquinolones, from the cell, and the
development of bypass pathways such as
expression of the alternative penicillin
binding protein (PBP2a) by MRSA.8,9
Bacteria may also develop resistance
through acquisition of genetic material
from other resistant organisms, usually by
conjugation  or  transformation.  Three
case studies of the emergence of drug
resistance, often to several different
compounds at the same time, illustrate the
different mechanisms by which resistant
bacteria develop.8
Bacterial resistance develops to the
commonly used ocular antibiotics, the flu-
oroquinolones, the aminoglycosides and
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chloramphenicol, when used for systemic
infections but the mechanisms are very
different. Recent studies have shown
increasing resistance to systemic use of
nalidixic acid, a quinolone, in Salmonella
enterica isolates in Korea11 and the isola-
tion of strains of Vibrio fluvalis resistant to
nalidixic acid and ciprofloxacin in India.12
Two mechanisms contribute to the devel-
opment of resistance to fluoroquinolones:
amino acid mutations in DNA gyrase and
topoisomerase IV and over-production of
the AcrAB efflux pump encoded by Cme-
ABC.13,14 Bacteria with the amino acid
mutations do not have the binding site for
the fluoroquinolones; for example, a sin-
gle point mutation (change of threonine
to isoleucine at codon 86) caused a 128-
fold increase in the minimal inhibitory
concentration for ciprofloxacin.14 Over-
expression  of  the  efflux  pump  allows
the bacteria to remove the antibacterial
compound, resulting in bacterial survival.
Current studies on the mechanisms of
resistance may allow the development of
chemicals to prevent resistance. An exam-
ple is the role of the repressor protein
LexA and the associated derepression of
three specialised DNA polymerases in the
evolution of resistance to ciprofloxacin,
demonstrating that LexA cleavage and
polymerase derepression are required for
the evolution of resistance.15 Thus, com-
pounds that inhibit LexA and the DNA
polymerases  should  efficiently  prevent
the development of fluoroquinolone
resistance.
In bacteria, especially Gram-negative
bacteria, chloramphenicol is inactivated
by the enzyme, chloramphenicol acetyl-
transferase. This resistance is borne by
plasmids, defined as closed loops of DNA
free in the bacterial cytoplasm that can
replicate on their own. These plasmids
often confer multi-drug resistance to the
bacteria, for example the resistance of
Salmonella enterica to ampicillin, strep-
tomycin, sulphonamides and tetracyclines
as well as chloramphenicol.16 Plasmids
may also be involved in inactivation of
aminoglycosides, which usually occurs by
phosphorylation with kinases, adenylation
with O-adenyltransferases or acetylation
with N-acetyltransferases.16
BACTERIAL RESISTANCE IN 
OCULAR ISOLATES
Fluoroquinolones have been in wide-
spread use as topical treatment for ocular
infections since about 1990. Resistance to
ciprofloxacin in ocular isolates of Staphylo-
coccus aureus from patients with bacterial
keratitis in Pittsburgh showed an increase
from 5.8 per cent in 1993 to 35.0 per cent
in 1997.17 In contrast, a retrospective
review of 1,312 bacterial isolates from
patients with keratitis in London between
1984 and 1999, including 33.4 per cent
with S. aureus, did not show an increased
proportion of isolates resistant to ofloxa-
cin, but rather a significant increase in
chloramphenicol resistance in Gram-neg-
ative bacteria.18 High susceptibility to the
fluoroquinolones (90 to 95 per cent) has
been reported in ocular bacterial isolates
from 1985 to 2000 in São Paulo, Brazil.19
Of 532 isolates from European centres
during 2001 and 2002, 5.5 per cent were
resistant to the new fluoroquinolone, gat-
ifloxacin, 11.7 per cent were resistant to
ofloxacin and 12.4 per cent were resistant
to ciprofloxacin.20 The introduction of
new fluoroquinolones, such as gatifloxa-
cin appears to delay but not to prevent the
development of resistance. The incidence
of resistance to ciprofloxacin in methicil-
lin-sensitive S. aureus isolates from ocular
infections was eight per cent in 1990 to
1995 but increased to 20.7 per cent in
isolates from 1996 to 2001.21 Further, the
resistance to ciprofloxacin in methicillin-
resistant S. aureus was 55.8 per cent in
1990 to 1995 and 83.7 per cent in 1996 to
2001. In these isolates, gentamicin suscep-
tibility remained high at 99 per cent for
methicillin-sensitive isolates and 86 per
cent for methicillin-resistant isolates.21
High rates of resistance of methicillin-
resistant S. aureus in ocular isolates to gat-
ifloxacin (71 per cent), moxifloxacin (68
per cent), ciprofloxacin and ofloxacin
(both 94 per cent) contrasted with com-
plete sensitivity of these isolates to vanco-
mycin and the low incidence of resistance
(three per cent) to gentamicin.22 Methicil-
lin-resistant S. aureus ocular infections are
still an infrequent cause of eye infections
overall, accounting for three per cent of
S. aureus infections in a major UK oph-
thalmic hospital,23 although methicillin-
resistant S. aureus were present in 57 per
cent of conjunctival bacterial isolates from
elderly patients in Japan.24 In the UK
study, all methicillin-resistant isolates were
sensitive to chloramphenicol, while 81 per
cent of isolates in the Japanese study were
sensitive to chloramphenicol. A recent
case study reported community-acquired
methicillin-resistant S. aureus in chronic
dacryocystitis in an 8.5-month-old boy.25
Bacterial cultures showed sensitivity to
gentamicin and vancomycin and resis-
tance to amoxicillin and erythromycin.25
Resistance to chloramphenicol has
been reported in these studies. The sensi-
tivity of S. aureus isolates was 85 per cent
in corneal samples and 92 per cent in con-
junctival samples in Brazil,19 while 14.1 per
cent of ocular samples were resistant to
chloramphenicol in Europe.20 Both stud-
ies tested the sensitivity to gentamicin
showing 72 per cent of S. aureus isolates
from the cornea and 79 per cent from
conjunctival isolates were sensitive in 1997
to 200024 and that 24.3 per cent of isolates
were resistant.20
It is worth noting that these definitions
of resistance are based on results from
standard routine tests from clinical micro-
biology laboratories and interpreted using
achievable blood concentrations of the
particular antibiotic. Direct application of
topical antibacterial agents to the eye
should result in initial high concentra-
tions, much greater than those achieved
in the blood and much higher than mini-
mal inhibitory concentrations for most
bacteria.26 However, these high concentra-
tions will dissipate much more rapidly
than in the blood.26 The pharmacokinetics
of antibacterial compounds at the ocular
surface remains under-researched.
POTENTIAL FOR SYSTEMIC 
RESISTANCE AFTER OCULAR 
ADMINISTRATION
Thus, resistance has been reported widely
with use of the fluoroquinolones, the ami-
noglycosides and chloramphenicol, both
for systemic and ocular treatment. The key
question becomes whether drug use in the
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eyes can produce systemic resistance and
potentially failure of systemic antibacterial
therapy. In addition to the development
of resistance by bacteria, the prerequisite
for this to occur is the absorption of drugs
into the body after ocular administration.
After oral administration (for example,
swallowing a tablet), the most popular
route of drug administration, drugs pass
from the stomach and intestine across the
stomach or intestinal wall to the blood ves-
sels before distribution to the rest of the
body. To be absorbed, drugs need both
water and lipid solubility; water solubility
in the gastrointestinal contents and blood
and lipid solubility to pass across the lipid
layer of the cells that form the wall of the
gastrointestinal tract. Many drugs such as
aspirin and codeine are partly ionised
depending on the pH of the solution that
the drug is in, for example, aspirin is
much more ionised in the acidic environ-
ment of the stomach than in the relatively
neutral pH of the blood. Gentamicin dem-
onstrates the necessity for both lipid and
water solubility for oral absorption. This
compound is extremely water-soluble with
effectively no solubility in the lipid layers.
As such, it is orally inactive and must be
given by intravenous injection to achieve
antibacterial concentrations in the blood.
Passage of drugs into the bloodstream
following topical application to the eyes
will also follow the same principles. There
is nothing unique about drug transport
across the eyes. When given topically to
the eyes, an extremely water soluble com-
pound, such as gentamicin, will produce
localised effects on the surface of the eye
but very little to no systemic absorption
and thus no propensity to produce
unwanted systemic effects, including the
development of resistance. On the other
hand, lipid-soluble compounds should be
expected to enter the systemic circulation
following topical administration to the
eyes. A therapeutic or toxic systemic re-
sponse will occur only if sufficient drug
has been absorbed. Thus, the dose given
will also play a major role in the determi-
nation of adverse effects.
These  concepts  can  be  demonstrated
by the β-adrenoceptor antagonist, timolol,
used as eye-drops for the treatment of
glaucoma. Adverse systemic effects from
timolol eye drops have been reported,
especially in the elderly, and include con-
gestive heart failure, arrhythmias, sinus
arrest, bronchospasm, central nervous
system effects such as dizziness, depres-
sion, nightmares, headache, somnolence,
insomnia, tinnitus, bizarre dreams and
dyslipidaemia.27 The Australian Medicines
Handbook (2003) includes bradycardia as
common (one to 10 per cent incidence)
following  the  use  of  timolol  eye  drops
with the following adverse effects as in-
frequent (less than one per cent inci-
dence): hypotension, syncope, impotence,
decreased libido, fatigue, confusion, hal-
lucinations, bronchospasm. It is relevant
to note here that glaucoma is much more
prevalent in the older population; other
concurrent disease states associated with
the ageing population may also cause
these responses. It is not possible to com-
pare the doses used for ocular and oral
therapy as timolol is available only for ocu-
lar use. One drop of timolol 0.5 per cent
twice daily is a daily dose of about 0.5 mg;
in contrast, the recommended oral dose
for metoprolol in the treatment of hyper-
tension is 50 to 100 mg daily.
Chloramphenicol  is  orally  active  and
so can pass across lipid membranes. The
manufacturer of chloramphenicol, Pfizer
Pty Ltd, has supplied the following
comment for inclusion in the Australian
Prescription Products Guide: that ‘Bone
marrow hypoplasia, including aplastic
anaemia and death, has been reported fol-
lowing local application of chlorampheni-
col’. Again, the different concentrations
need to be considered: chloramphenicol
eye-drops given as two drops two- to six-
hourly will produce a daily dose of two to
10 mg, while the recommended oral dose
of chloramphenicol for typhoid fever is
one gram six-hourly or four grams each
day. A similar difference in dosage applies
for ciprofloxacin: 0.3 per cent eye-drops
given as two drops four-hourly produces a
daily dose of about two milligrams, while
the recommended treatment for bron-
chial infections is 500 mg every 12 hours
(one gram per day).
Thus, antibacterial compounds with
some lipid solubility, such as the fluoroqui-
nolones and chloramphenicol should be
expected to pass into the systemic circula-
tion after ocular administration, to give
low concentrations in the circulation.
Such low antibiotic concentrations follow-
ing ocular administration could provide
the selective pressure for resistant bacteria
to survive. A thorough search of the
PubMed database did not produce any
reports of systemic resistance produced
by ocular application of antibacterial
compounds such as gentamicin, tobra-
mycin, chloramphenicol, ciprofloxacin or
ofloxacin. In principle, short-term treat-
ment, suggested to be the norm by optom-
etrists, should produce less resistance than
long-term treatment with antibacterial
eye-drops.
STRATEGIES TO DEAL WITH 
BACTERIAL RESISTANCE
Antibiotic treatment and the development
of bacterial resistance are not confined to
ocular infections and so concepts devel-
oped for systemic infections may be useful
for the control of ocular infections. The
Therapeutic Guidelines series provides an
independent consensus and interpreta-
tion of clinical evidence by an expert Aus-
tralian group of experienced clinicians
and pharmacists. One of these volumes,
the Antibiotic Guidelines,28 provides use-
ful suggestions for treatment of patho-
gens. The evaluation of an inadequate
response to antibiotic treatment is com-
plex; an algorithm has recently been
provided as an approach to apparent
antibiotic failure.29
The discovery of effective and safe anti-
biotics over the past 50 to 70 years may
lead to the complacent view that new anti-
biotics will always be available to combat
new infectious diseases. This may be pos-
sible if exciting new technologies, includ-
ing genomics and structural biology, are
used to extend the treatment options.30
The problems of bacterial resistance are
remarkably complex; a very interesting
collection of viewpoints has just been
published until the title ‘Anti-infective
research and development—problems,
challenges, and solutions’ in Lancet Infec-
tious Diseases.31
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